

Amit G Patel & Associates

Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

To, The Members, SOTAC RESEARCH PRIVATE LIMITED CIN NO-U73100GJ2019PTC108144

Report on the Financial Statements

We have audited the accompanying (Standalone) financial statements of **SOTAC RESEARCH PRIVATE LIMITED (CIN NO-U73100GJ2019PTC108144)** ("the Company"), which comprises the Balance Sheet as at 31st March, 2021, the Cash Flow Statement for the year then ended, and a summary of the significant Accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



D-408, Safal - Sumel Business Park-6, Dudheshwar Road, Dudheshwar, Ahmedabad - 380004
+91 78788 11850
caamitgpatel@gmail.com

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the company has in place an adequate internal financial control system over financial reporting and the operating effectiveness of such control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the (Standalone) financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2021, and its cash flows for the year ended on that date.



Report on Other Legal and Regulatory Requirements

- 1. As required by the Companies (Auditors' Report) Order, 2016 ("the order"), as amended, issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, CARO,2016 not applicable to Private company whose :
 - i. Not a holding or subsidiary of a Public company

ii. Paid up Capital plus Reserves less than or equal to Rs. 1 Crore as at the reporting date

iii. Borrowings less than or equal to Rs. 1 Crore at any time during the year

iv. Revenue less than or equal to Rs. 10 Crores in the financial year

2. As required by Section 143 (3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The Balance Sheet and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements generally comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed effect of pending litigation on its financial position in its financial statements Refer Note (9) to the financial statement for contingent liabilities



- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For, Amit G Patel & Associates **Chartered Accountants** FRN No: 152837W



Proprietor Mem No : 197675

Date : 15/11/2021 Place : Ahmedabad

UDIN: 22197675AAAAAM1968

Annexure "A" to the Independent Auditor's Report of even date on the Financial Statement of SOTAC RESEARCH PRIVATE LIMITED (CIN NO-U73100GJ2019PTC108144)

Report on the Internal Financial Control under Clause (i) of Sub-section 3 of section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial control over financial reporting of **SOTAC RESEARCH PRIVATE LIMITED (CIN NO-U73100GJ2019PTC108144)** ("the Company") as of March 31, 2021 in Conjunction with our audit of the financial statement of the Company for the year ended on the date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for stabling and maintaining internal financial control based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities includes the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the companies Act, 2013, to the extent applicable to an audit of Internal Financial controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirement and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves Performing procedure to obtain the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting includes an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depends on the auditor's Judgement, including the assessment of the risks of material misstatement of the financial statement. Whether due to fraud or error.



We believe that the audit evidence we have is sufficient and appropriate to provide a basis for our audit opinion on the company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principal. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transaction and dispositions of the assets of the company; (2) provide reasonable assurance that transaction and recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls over Financial Reporting

Because of the inherent limitation of internal financial control over financial reporting, including the possibility of collusion or improper management override of control, material misstatements due to error or fraud may occur and not be detected. Also, projection of any evaluation of the internal financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that degree of compliance with policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Control over financial Reporting issued by the Institute of Chartered Accountants of India.

For, Amit G Patel & Associates Chartered Accountants FRN No : 152837W

Ropater

CA Amit G Patel Proprietor Mem No : 197675 Date : 15/11/2021 Place : Ahmedabad UDIN : 22197675AAAAAM1968



Particulars	Sch. No.	31.03.2021	31.03.2020
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	1	10,00,000	10,00,000
(b) Reserves and Surplus	2	(1,97,224)	(1,75,068
(c) Money Received Against Share Warrants			
(2) Share Application Money Pending Allotment		101	
(3) Non-Current Liabilities			
(a) Long-Term Borrowings	3	5,80,891	5,56,001
(b) Deferred Tax Liabilities (Net)			
(c) Other Long Term Liabilities			-
(d) Long Term Provisions		-	
(e) Other Non Current Liabilities		-	· ·
(4) Current Liabilities			
(a) Short-Term Borrowings	4		
(b) Trade Payable	5	4,09,559	6,72,08
(c) Other Current Liabilities	6		-
(d) Short-Term Provisions	7	a second	-
Total Equity & Liabilities		17,93,226	20,53,01
II.ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets	8		
(i) Gross Block		16,14,411	16,95,74
(ii) Depreciation		3,18,999	2,26,44
(iii) Net Block		12,95,412	14,69,30
(b) Non-Current Investments	1.000		-
(c) Deferred Tax Assets (Net)			-
(d) Long Term Loans and Advances		-	-
(e) Other Non-Current Assets	9	-	-
(2) Current Assets			
(a) Current Investments			
(b) Inventories	10		*
(c) Trade Receivables	11	3,44,908	2,90,80
(d) Cash and Cash Equivalents	12	22,956	40,24
(e) Short-Term Loans And Advances	13	1,29,950	2,52,66

Plot No. PF-21, Nr ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Ahmedabad 382110

NOTES TO ACCOUNTS 22 Schedules referred to above and notes attached there to form an integral part of Balance Sheet This is the Balance Sheet referred to in our Report of even date.

Total Assets

21

For, Amit G Patel & Associates

CH PRIL CHARTERED ACCOUNTANTS pahi AS. 30 M.No. 197675 Kø 3100GJ2019 AC U FRN No. 152837W PTC108144 CA Amit G Patel A'BAD 4 Proprietor Membership No. : 19767 AYMEDAB PEDACCO Firm Reg. No.: 152837W

SHARAD PATEL Director

17,93,226

For, SOTAC RESEARCH PRIVATE LIMITED

CHETAN PATEL Director Din No-07252116

0

20,53,018

PLACE : AHMEDABAD DATE : 15/11/2021

UDIN : 22197675AAAAAM1968

(f) Other Current Assets

Significant Policies

Din No-07252252

Plot No. PF-21, Nr ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Ahmedabad 382110 PROFIT & LOSS STATEMENT FOR THE PERIOD ENDED ON 31ST MARCH,2021

-	Particulars	Sch. No.	31.03.2021	31.03.2020
1	Revenue from operations	14	9,21,656	12,36,196
	Other Income	15		15,000
m	III. Total Revenue (I +II)		9,21,656	12,51,196
	Expenses:	10	2 62 224	4 00 640
	Cost of materials consumed	16	2,83,231	4,89,643
	Changes in inventories of finished goods, work-in- progress and Stock-in-Trade	17		
	Employee Benefit Expense	17 18	1,39,400	99,717
	Financial Costs	19	5,550	6,431
	Depreciation and Amortization Expense	8	3,18,999	2,25,440
	Other Administrative Expenses	20	1,96,632	6,04,033
	Total Expenses (IV)		9,43,812	14,26,264
1	Profit before exceptional and extraordinary items and			
V	tax	(III - IV)	(22,156)	(1,75,068
VI	Exceptional Items		-	
VII	Profit before extraordinary items and tax (V - VI)	-	(22,156)	(1,75,068
VIII	Extraordinary Items			-
IX	Profit before tax (VII - VIII)	-	(22,156)	(1,75,068
x	Tax expense:			
	(1) Current tax (2) Deferred tax		-	
	(3) MAT Credit (Entitledment)		-	
XI	Profit(Loss) from the perid from continuing operations	(IX-X)	(22,156)	(1,75,068
хи	Profit/(Loss) from discontinuing operations			
xIII	Tax expense of discounting operations		· ·	-
XIV	Profit/(Loss) from Discontinuing operations (XII - XIII)			
	Profit/(Loss) for the period (XI + XIV)		(22,156)	(1,75,068
XV I		-		(1), 0,000
	Earning per equity share: (1) Basic		(0.22)	(1.75

Plot No. PF-21, Nr ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Ahmedabad 382110 Schedules Forming IntegralPart Of Balance Sheet as at 31st March 2021

Sr. No	Particulars	31.03.2021	31.03.2020
1	AUTHORIZED CAPITAL 1,00,000 Equity Shares of Rs. 10/- each.	10,00,000	10,00,000
		10,00,000	10,00,000
2	ISSUED, SUBSCRIBED & PAID UP CAPITAL To the Subscribers of the Memorandum 1,00,000 Equity Shares of Rs. 10/- each.	10,00,000	10,00,000
	Total in	10,00,000	10,00,000

The details of share holders holding more than 5% of shares as at 31st March, 2021 are as follows:

Sr. No.	Name of the Share Holder	As at 31St March, 2021	
	Name of the share holder	No. of Shares	% Held
1	Kiranben Baldevbhai Jotania	20,000	20.00%
-	Chetankumar Bachubhai Patel	20,000	20.00%
	Dineshkumar Babulal Gelot	20,000	20.00%
	Vasantkumar Devarajbhai Patel	20,000	20.00%
	Sharadkumar Dasharathbhai Patel	20,000	20.00%

Sr. No.	Name of the Share Holder	As at 31St March, 2020		
	Name of the share Holder	No. of Shares	% Held	
	Kiranben Baldevbhai Jotania	20,000	20.00%	
	2 Chetankumar Bachubhai Patel	20,000	20.00%	
	B Dineshkumar Babulal Gelot	20,000	20.00%	
	Vasantkumar Devarajbhai Patel	20,000	20.00%	
	5 Sharadkumar Dasharathbhai Patel	20,000	20.00%	

Schedule : 2 Reserve & Surplus

Sr. No	Particulars	31.03.2021	31.03.2020
1	Securities Premium reserve	(1,75,068)	-
2	Surplus (Profit & Lass Account)	(22,156)	(1,75,068)
	Total in	(1,97,224)	(1,75,068)

Schedule : 3 Long Term Borrowings

Sr. No	Particulars		31.03.2021	31.03.2020
	Unsecured loan			
	From Directors		and the second sec	
	Baldevbhai T Jotania (Kiranben)		1,00,000	1,00,000
	Chetankumar B Patel	1. 199.00	1,80,891	1,56,001
	Dineshkumar B Gelot		1,00,000	1,00,000
	Sharadkumar D Patel		1,00,000	1,00,000
	Vasant D Patel		50,000	50,000
		Sub Total (a)	5,30,891	5,06,001
	From Related Parties			
	Vishal D Patel		50,000	50,000
		Sub Total (b)	50,000	50,000
-	Total		5,80,891	5,56,00





Schedule : 4 Short Term B

Sr. No	Particulars	31.03.2021	31.03.2020
	Loan Repayable on Demand		-
1	Cash Credit Account		
	Secured by Equitable Mortgage on the Stock, Debtors and		
	other current assets of the company		
	Total in		

Schedule : 5 Trade Payable

Sr. No	Particulars	31.03.2021	31.03.2020
1	A B Febrication	88,500	88,500
2	Amit G Patel & Associates	20,000	32,500
3	Kesar Control System		14,046
4	Raj Tech		540
5	Rakesh Chemicals		26,114
6	Shree Sidhivinayak Enterprise		4,489
7	Sotac Pharmaceuticals Pvt Ltd		3,63,198
8	Stepup Enterprise		52,700
9	Umiya Enterprise		90,000
10	V R Patel & Associates	24,000	
11	Brahmani Engineering	5,900	
12	Niyama Tradelink	3,970	
13	Shree Sidhivinayak Enterprise	4,489	
14	Sotac Pharmaceuticals Pvt Ltd		
15	Stepup Enterprise	52,700	
16	Umiya Enterprise	90,000	
17	Unpaid Salary	1,20,000	
	Total in	4,09,559	6,72,08

Schedule : 6 Other Current Liabilities

Sr. No	Particulars	31.03.2021	31.03.2020
Total in			

Schedule : 7 Short Term Provisions

Sr. No	Particulars		31.03.2021	31.03.2020
	Total in	NEW MERINA		

chedule : 9 Other N	on Current Assets		
Sr. No	Particulars	31.03.2021	31.03.2020
Total in			

Schedule : 10 Inventories

Sr. No	Particulars	31.03.2021	31.03.2020
Total	in	-	

Schedule : 11 Trade Receivables

No. 152837 BAD

2BFA Pharma India LLP-3Brunex Pharmaceuticals Pvt Ltd17,7004Anya Biopharma India LLP Maharashtra2,72,5005BFA Pharma India LLP49,0006Sotac Healthcare Private Limited4,7207Sotac Pharmaceuticals Private Limited988	1	Particulars	31.03.2021	31.03.2020
3Brunex Pharmaceuticals Pvt Ltd17,7004Anya Biopharma India LLP Maharashtra2,72,5005BFA Pharma India LLP49,0006Sotac Healthcare Private Limited4,7207Sotac Pharmaceuticals Private Limited988	A	Advance Paid to Creditors		1,65,106
4Anya Biopharma India LLP Maharashtra2,72,5005BFA Pharma India LLP49,0006Sotac Healthcare Private Limited4,7207Sotac Pharmaceuticals Private Limited988	В	BFA Pharma India LLP		1,08,000
5 BFA Pharma India LLP 49,000 6 Sotac Healthcare Private Limited 4,720 7 Sotac Pharmaceuticals Private Limited 988	B	Brunex Pharmaceuticals Pvt Ltd	17,700	17,700
6 Sotac Healthcare Private Limited 4,720 7 Sotac Pharmaceuticals Private Limited 988	A	Anya Biopharma India LLP Maharashtra	2,72,500	
7 Sotac Pharmaceuticals Private Limited 988	B	BFA Pharma India LLP	49,000	-
	S	Sotac Healthcare Private Limited	4,720	-
Total in 3,44,908	S	Sotac Pharmaceuticals Private Limited	988	
	T	fotal in	3,44,908	2,90,806
				1

Sr. No	Particulars		31.03.2021	31.03.2020
1	Cash-in-Hand		A Providence	
	Cash Balance		3,239	40,000
		Sub Total (A)	3,239	40,000
2	Bank Balance			
	Axis Bank Ltd		19,717	245
		Sub Total (B)	19,717	246
3	Fixed Deposit			
		Sub Total (C)		-
	Total [A + B+C]		22,956	40,246
chedule	:13 Short Terms Loans and Advances			
Sr. No	Particulars		31.03.2021	31.03.2020
1	Rent Deposit		-	42,000
2	TDS Recevable		78,925	38,800
	Decisie chart of the second		51,025	1,71,860
3	GST Receivable		51,025	1,7 1,000





Plot No. PF-21, Nr ACME Pharma, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Ahmedabad 382110

Schedules Forming Part of the Profit & Loss Accounts as at 31st March 2021

Schedule : 14 Revenue from Operations

Sr. No	Particulars	31.03.2021	31.03.2020
1	Net Sales	9,21,656	12,36,196
	Total in	9,21,656	12,36,196

Schedule : 15 Other Income

Sr. No	Particulars	31.03.2021	31.03.2020
1	Service Income		15,000
	Total in		15,000

Schedule : 16 Cost of Material Consumed

Sr. No	Particulars		31.03.2021	31.03.2020
a)	PURCHASES OF RAW MATERIALS AND S	TORES		
1	Purchase		2,78,351	4,52,304
		Sub-total (a)	2,78,351	4,52,304
b)	DIRECT/PRODUCTIONS EXPENSES			
1	Electricity Expense	AC IN MALLIN	4,880	37,339
		Sub-total (b)	4,880	37,339
	Total in		2,83,231	4,89,643

Schedule : 17 Change in Inventories

Sr. No	Particulars	31.03.2021	31.03.2020
1	Opening Stock		-
2	Closing Stock		
	Total in		-

Schedule : 18 Employement Benefit Expenses

Sr. No	Particulars	31.03.2021	31.03.2020
1	Salaries, Bonus, PF & ESIC	1,39,400	99,717
2	Staff Welfare Expense		-
3	Director Remuneration		-
	Total in	1,39,400	99,717

CH PRI

Scedule : 19 Financial Cost

31.03.2021 31.03.2020 Sr. No Particulars Interest to Bank: 1 3100GJ2019 Interest on Cash Credit Facality C10814 Interest on Term loan Interest on Vehicle Loan MEDI H.No. 19767 Others (Bank Charges) 5,550 6,431 2 Total in 10. 5,550 6,431 EDAC

Schedule : 20 Other Administrative Expenses

Sr. No	Particulars	31.03.2021	31.03.2020	
1	Audit Fees	15,000	7,500	
2	Accounting & GST Fees	24,000	17,500	
3	Company Incorporation Expense		31,990	
4	ROC Expense	5,000	7,500	
5	Repairing & Maintaince Exp-Computer	33,545	540	
6	FDA Test Expense & Government Fees	21,159	500	
7	Febrication Expense	-	36,760	
8	Legal Fees	-	18,285	
9	Maintainance Expense	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	28,750	
10	Municipal Tax-Office		31,175	
11	Rent Expense-Office	80,000	4,20,000	
12	Fire Extingisher	-	2,500	
13	Kasar & Discount	2	124	
14	Petrol & Fuel Expense (Travelling)	14,526	909	
15	Cartage Expense-Freight	800	-	
16	Freight Expense	2,600	-	
	Total in	1,96,632	6,04,033	





					SOTAC	RESEARCH PRIVATE	LIMITED					1
	in the second second			Plot No. PF-21,	Nr ACME Pharma, Opp	p. Teva Pharma, Sana	nd GIDC-II, Sanand,	Ahmedabad 3821	10			
				Sche	dules Forming Integra	I Part of the Balance	Sheet as at 31st Ma	arch, 2021				
Sched	dule : 8 Fixed Asset											
. Fixe	ed Assets										and the second s	
				Gross	Block			Depreci	ation		Net Block	
Sr. No	Particulars	Rate	01.04.2020	Addition during the year	Deduction during the year	31.03.2021	01.04.2020	Addition during the year	Deduction during the year	31.03.2021		WDV as on 31.03.2020
	Tangible Assets											
1	Computer & Printer	63.16%	25,001	-		25,001	15,791		-	15,791	9,210	25,00
2	Plant & Machinery	18.10%	13,76,912			13,76,912	2,49,221	-		2,49,221	11,27,691	13,76,9
3	Furniture	25.89%	67,393	1,45,105		2,12,498	17,449	36,538		53,987	1,58,511	67,39
	Intangible Assets			-								
-	TOTAL		14,69,306	1,45,105		16,14,411	2,82,461	36,538	-	3,18,999	12,95,412	14,69,30





Significant Accounting Policies

NOTE: 21

A. Basic of Preparation of Financial Statements

The financial statement have been prepared under the historical cost convention on going concern basis in accordance with the generally accepted accounting principles in India and mandatory accounting standards issued by the Institute of Chartered Accountants of India and the applicable accounting standards notified under the Companies (Accounting Standards) Rules, 2006. All income and expenditures having material bearing on the Financial Statements are recognized on accrual basis.

B. Use of Estimates

The preparation of financial statement requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the results are known\materialized.

C. Own Fixed Assets

Fixed assets are stated at cost net of modvat / cenvat less depreciation. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the fixed assets are capitalized.

D. Leased Assets

Operating Lease: Rentals are expensed with reference to Leased terms and other considerations.

E. Preliminary Expenses

Preliminary Expenses are allocated to the cost of building and machineries on the basis of cost incurred.

F. Depreciation

Depreciation is provided, on a Pro-rata basis, from the date of the Assets have been installed and put to use, on Straight Line Method. Depreciation is provided on the basis of useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.

G. Impairment of Assets

During the year, the carrying cost of assets does not exceed its recoverable value, Hence Impairment Profit/Loss is not charged to Profit and Loss Account.





H. Foreign Currency Transactions

- a) Transactions denominated in foreign currencies are normally at the exchange rate prevailing at the time of the transaction.
- b) Any income or expense on account of exchange difference either on settlement or on translation is recognized in the profit and loss account except in cases where they relate to acquisition of fixed assets in which case they are adjusted to the carrying cost of such assets.

I. Inventories

Items of inventories are measured at lower of cost or net realizable value. Cost of inventories comprises of all cost of purchase cost of conversion and other costs incurred in bringing them to their respective present location and condition. Cost of raw materials, stores and spares, packing materials and Fuel are determined on weighted average basis. Cost of work-in-progress is determined on absorption costing method. Valuation of Finished Goods is cost or net realization value, whichever is less.

J. Turn Over

Turnover includes sale of Goods at Head Office and Branches, sales tax and Excise duty.

K. Excise Duty and Sales Tax and Goods and Services Tax

Excise duty has been accounted on the basis of payments made in respect of goods cleared. Sales Tax and Goods and service Tax is charged to Profit and Loss Account.

L. Employee Retirement benefits

Company's contribution to Provident fund is charged to Profit and Loss Account. Provision for Leave encashment liability is not accounted as the company is not liable for any leave encashment liability as on 31st March, 2021.

Company is accounting for gratuity on actual basis.

M. Borrowing Costs

Borrowing costs that are attributable to the acquisition, construction of qualifying assets are capitalized as part of the cost of such assets till the month in which the assets is ready for use. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to Profit and loss Account as an expense in the period in which these are incurred.

N. Provision for Current and Deferred Tax

Provision for current tax is made after taking in to consideration benefits admissible under the provisions of the Income Tax Act, 1961. Deferred Tax resulting from " Timing Difference " Between Book and Taxable Profit is accounted for using the Tax rates and laws that have been enacted or substantively enacted as on the Balance sheet date.



3100GJ2019

O. Provision, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities\Assets are neither recognized nor disclosed in the financial statements.

As per our report of even date attached.

For, Amit G Patel & Associates Chartered Accountants FRN No. 152837W



CA. Amit G Patel Proprietor Mem No. 197675

Date: - 15/11/2021 Place:-Ahmedabad UDIN : 22197675AAAAAM1968 For, SOTAC RESEARCH PRIVTE LIMITED CIN NO-U73100GJ2019PTC108144

Sharad Patel Director DIN No-07252252



Chetan Patel Director DIN No-07252116

Notes on Accounts

Schedule : 22

- 1. The previous year figures have been reworked, regrouped, rearranged and reclassified wherever necessary. Accordingly, amounts and other disclosures for the preceding year are included as an integral part of the Current year financial statements and are to be read in relation to the amounts and other disclosures relating to the current year.
- 2. The Fixed assets have not been revalued during the year.
- **3.** The Semi-Finished goods have been valued by including the direct production related Overheads. The Raw Material cost is calculated by including direct expenses related to raw material purchase e.g. raw material transportation exps.

4. Segment Reporting :

The company does not have more than one reportable segment, accordingly pursuant to AS-17 on Segment Reporting issued by the ICAI, Hence Segmental information is not required to provide.

5. Value of the Raw Material Consumed:

		(In Rupees
	2020-21	2019-20
Indigenous	NIL	NIL
Imported	NIL	NIL

6. As per Accounting standard 18, issued by the Institute of Chartered Accountants of India, The disclosures of transactions with the related parties as defined in the Accounting Standard are given below:

Name of Party	Relation	Nature of transaction	Amount (Rs.)
	NA		

7. Earnings per Share (EPS) - The numerator and denominator used to calculate Basic and Diluted Earnings per Share:

	(Amount in Rs.)	
Particulars	2020-21	2019-20
Profit attributed to the equitable shareholders used as numerator – (A)	-22,156	-1,75,068
The weighted average number of equity shares outstanding during the year used as denominator – (B)	1,00,000	1,00,000
Basic/ Diluted Earnings Per Share (Rs.) - (A)/ (B)	-0.22	-1.75





8. Auditors' Remuneration is made up of:

		(Amount in Rs
F.Y. Year	2020-21	2019-20
Audit Fees	15,000/-	0/-

As per our report of even date attached.

For, Amit G Patel & Associates Chartered Accountants FRN No : 152837W

CALLE STATE

RAD

11

CA. AMIT G PATEL Proprietor Mem No. 197675

Date: - 15/11/2021 Place:-Ahmedabad UDIN : 22197675AAAAAM1968 For, SOTAC RESEARCH PRIVATE LIMITED. CIN NO-U73100GJ2019PTC108144

Sharad Patel Director DIN No-07252252

ACH PRI 3100GJ201 PTC108144 MED

Chetan Patel Director DIN No-07252116

22197675AAAAAM1968